On the other hand, although there are data to support the critical role of ESRPs in cancer in preclinical and clinical settings, it will be challenging to characterize ESRPs as drug targets due to the different mechanisms of ESRP1 and ESPR2 in the regulation of EMT and the lack of a protein crystal structure [32]. Here, ESRP1 is linked to cancer.